Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
Rheumatology (Oxford). 2024 Mar 1;63(3):639-647. doi: 10.1093/rheumatology/kead280.
Rheumatology (Oxford). 2024.
PMID: 37294870
Free PMC article.
Clinical Trial.
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.
Khanna D, Maher TM, Volkmann ER, Allanore Y, Smith V, Assassi S, Kreuter M, Hoffmann-Vold AM, Kuwana M, Stock C, Alves M, Sambevski S, Denton CP.
Khanna D, et al. Among authors: sambevski s.
RMD Open. 2023 Feb;9(1):e002859. doi: 10.1136/rmdopen-2022-002859.
RMD Open. 2023.
PMID: 36796874
Free PMC article.
Clinical Trial.
Item in Clipboard
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D, Denton CP, Wuyts WA, Miede C, Alves M, Sambevski S, Allanore Y.
Volkmann ER, et al. Among authors: sambevski s.
Rheumatology (Oxford). 2022 Nov 2;61(11):4397-4408. doi: 10.1093/rheumatology/keac091.
Rheumatology (Oxford). 2022.
PMID: 35150246
Free PMC article.
Clinical Trial.
Item in Clipboard
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S.
Patorno E, et al. Among authors: sambevski s.
Circulation. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8.
Circulation. 2019.
PMID: 30955357
Free PMC article.
Item in Clipboard
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B.
Fitchett D, et al. Among authors: sambevski s.
Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.
Circulation. 2019.
PMID: 30586757
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite